Carl M. Kjellstrand
Research Subjects
Carl M. Kjellstrand has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Zbylut J. Twardowski
Department of Medicine, University of Missouri, Columbia, Missouri
4 shared publicationsChristopher R. Blagg
†Department of Medicine, University of Washington, Seattle, Washington
2 shared publications- Christopher R. Blagg
Department of Medicine, University of Washington, and Northwest Kidney Centers, Seattle, Washington, USA
2 shared publications - Amy W. Williams
Mayo Clinic, Rochester, MN 55905, USA
1 shared publication Barbara G. Delano
1 shared publicationBessie Young
1 shared publication
Latest Publications
- 1 October 2006
- Vol. 20 (11) , 56-7, 59
The Northwest Kidney Centers' experience with the Aksys PHD system.
- 1 October 2006
- Vol. 20 (11) , 56-7, 59
The Northwest Kidney Centers' experience with the Aksys PHD system.
- 29 March 2004
- Published by Wiley in Seminars in Dialysis
- Vol. 17 (2) , 151-153
APPROACHES TO QUOTIDIAN DIALYSIS: The Aksys Personal Hemodialysis System
The Aksys personal hemodialysis system empowers patients to dialyze where, when, and how they want. It allows them to easily do the best dialysis—daily hemodialysis—in the safest place—at home—by simplifying operation (almost anyone can do it), doing the drudgery work of dialysis (the patient is the master, not the slave of the dialysis machine, giving patients their lives back), needing no bulky disposables (patients have their homes back), reducing emergencies during dialysis, and performing immediate fluid resuscitation on demand.
- 29 March 2004
- Published by Wiley in Seminars in Dialysis
- Vol. 17 (2) , 151-153
APPROACHES TO QUOTIDIAN DIALYSIS: The Aksys Personal Hemodialysis System
The Aksys personal hemodialysis system empowers patients to dialyze where, when, and how they want. It allows them to easily do the best dialysis—daily hemodialysis—in the safest place—at home—by simplifying operation (almost anyone can do it), doing the drudgery work of dialysis (the patient is the master, not the slave of the dialysis machine, giving patients their lives back), needing no bulky disposables (patients have their homes back), reducing emergencies during dialysis, and performing immediate fluid resuscitation on demand.
- 1 January 2003
- Published by Wiley in Hemodialysis International
- Vol. 7 (1) , 67-71
Differences in Dialysis Practice Are the Main Reasons for the High Mortality Rate in the United States Compared to Japan
The cumulative survival of Japanese hemodialysis patients is more than 2.5 times better than that of dialysis patients in the United States (U.S.). The difference is particularly pronounced in older patients, being 4 times better in patients over the age of 50 years. The mortality in U.S. patients has increased from 10 to 25% over the last three decades, but has remained stable at around 10% in Japan. There is no obvious difference in patient selection. The Japanese accept almost as high a proportion of diabetic patients as does the United States, and the mean age of incident patients is higher in Japan. Renal transplantation, virtually absent in Japan, should increase mortality in U.S. dialysis patients by removing patients with the highest probability of survival, but even if one adds surviving transplant patients and studies prevalent populations, the survival rate is much better in Japan. Genetic factors are unlikely to explain differences in mortality, as older Americans live much longer than older Japanese. We speculate that the difference lies in the practice of dialysis. Patients in the United States are generally treated by much faster and shorter dialysis than in Japan. This puts a severe burden on the cardiovascular system of older patients, leading to the poorer survival rate. Japanese physicians also appear to be better trained in dialysis and to spend more time with their patients. The nursing shortage in the United States may also contribute to the increased mortality. Whatever the explanations, the U.S. dialysis community must work to equal and, hopefully, surpass the now superior survival of Japanese dialysis patients.
- 1 January 2003
- Published by Wiley in Hemodialysis International
- Vol. 7 (1) , 67-71
Differences in Dialysis Practice Are the Main Reasons for the High Mortality Rate in the United States Compared to Japan
The cumulative survival of Japanese hemodialysis patients is more than 2.5 times better than that of dialysis patients in the United States (U.S.). The difference is particularly pronounced in older patients, being 4 times better in patients over the age of 50 years. The mortality in U.S. patients has increased from 10 to 25% over the last three decades, but has remained stable at around 10% in Japan. There is no obvious difference in patient selection. The Japanese accept almost as high a proportion of diabetic patients as does the United States, and the mean age of incident patients is higher in Japan. Renal transplantation, virtually absent in Japan, should increase mortality in U.S. dialysis patients by removing patients with the highest probability of survival, but even if one adds surviving transplant patients and studies prevalent populations, the survival rate is much better in Japan. Genetic factors are unlikely to explain differences in mortality, as older Americans live much longer than older Japanese. We speculate that the difference lies in the practice of dialysis. Patients in the United States are generally treated by much faster and shorter dialysis than in Japan. This puts a severe burden on the cardiovascular system of older patients, leading to the poorer survival rate. Japanese physicians also appear to be better trained in dialysis and to spend more time with their patients. The nursing shortage in the United States may also contribute to the increased mortality. Whatever the explanations, the U.S. dialysis community must work to equal and, hopefully, surpass the now superior survival of Japanese dialysis patients.
- 1 January 2000
- Published by Wiley in Hemodialysis International
- Vol. 4 (1) , 15-17
Use of Systemic Blood Urea Nitrogen Levels Obtained 30 Minutes before the End of Hemodialysis to Portray Equilibrated, Postdialysis Blood Urea Nitrogen Values
- 1 January 2000
- Published by Wiley in Hemodialysis International
- Vol. 4 (1) , 15-17
Use of Systemic Blood Urea Nitrogen Levels Obtained 30 Minutes before the End of Hemodialysis to Portray Equilibrated, Postdialysis Blood Urea Nitrogen Values
- 1 December 1999
- Published by Wiley in Seminars in Dialysis
- Vol. 12 (6) , 403-405
Daily Hemodialysis Is Best: Why Did We Stop at Three?
- 1 December 1999
- Published by Wiley in Seminars in Dialysis
- Vol. 12 (6) , 403-405
Daily Hemodialysis Is Best: Why Did We Stop at Three?
- 1 January 1999
- Published by Wiley in Home Hemodialysis International
- Vol. 3 (1) , 13-15
Measurement of Hemodialysis Adequacy in a Changing World
Defining adequacy of dialysis remains an elusive goal. The application of the Kt/Vurea concept to clinical dialysis was a major improvement in trying to define a dialysis dose. Intuitively, the Kt/V concept makes a great deal of sense: the urea clearance of the dialyzer during dialysis (K), multiplied by the time (t) of dialysis, divided by the patient's urea distribution volume (V) ought to give the best number to compare the efficiency of dialyses that patients receive. There are, however, many pitfalls associated with the whole Kt/Vurea concept.
- 1 January 1999
- Published by Wiley in Home Hemodialysis International
- Vol. 3 (1) , 13-15
Measurement of Hemodialysis Adequacy in a Changing World
Defining adequacy of dialysis remains an elusive goal. The application of the Kt/Vurea concept to clinical dialysis was a major improvement in trying to define a dialysis dose. Intuitively, the Kt/V concept makes a great deal of sense: the urea clearance of the dialyzer during dialysis (K), multiplied by the time (t) of dialysis, divided by the patient's urea distribution volume (V) ought to give the best number to compare the efficiency of dialyses that patients receive. There are, however, many pitfalls associated with the whole Kt/Vurea concept.
- 1 January 1999
- Published by Wiley in Home Hemodialysis International
- Vol. 3 (1) , 13-15
Measurement of Hemodialysis Adequacy in a Changing World
- 1 January 1999
- Published by Wiley in Home Hemodialysis International
- Vol. 3 (1) , 13-15
Measurement of Hemodialysis Adequacy in a Changing World
- 1 October 1998
- Published by Elsevier in Advances in Renal Replacement Therapy
- Vol. 5 (4) , 267-274
Daily Hemodialysis: Dialysis for the Next Century
- 1 October 1998
- Published by Elsevier in Advances in Renal Replacement Therapy
- Vol. 5 (4) , 267-274
Daily Hemodialysis: Dialysis for the Next Century
- 5 January 1998
- Published by Wiley in Journal of Internal Medicine
- Vol. 243 (1) , 3-14
On the success, cost and efficiency of modern medicine: an international comparison
Kjellstrand CM, Kovithavongs C, Szabo E (University of Alberta, Edmonton, Canada). On the success, cost and efficiency of modern medicine: an international comparison. J Intern Med 1998; 243: 3–14.Objective: To study the success and cost of modern medicine in industrialized, rich countries from 1980 to 1990.Design: Cost per capita and per cent of gross domestic product (GDP) spent on health was related to: (i) mortality in six diseases amenable to treatment by modern medicine; (ii) the sum of those six diseases (avoidable disease); (iii) death due to other, unavoidable diseases; (iv) maternal and infant mortality; (v) life expectancy at birth; (vi) renal dialysis and transplantation rates. Efficiency was studied by comparing a country's avoidable mortality rates multiplied by expenses, to the mean for all countries.Results: During the 10 years, avoidable death rate decreased 38% but unavoidable death rate only 10%. Life expectancy increased 3%. Cost per capita increased 107% but health expenditures, as per cent of GDP only 10%. There was a reasonable correlation between expenses and avoidable mortality but none between expenses and unavoidable death rate. In 1990 avoidable mortality was lowest in Canada, and highest in Japan. Cost was lowest in New Zealand, and highest in the USA. The efficiency index was highest for Australia, and lowest in the USA.Conclusion: Modern medicine as we have studied it is successful. Avoidable death rate shows a steep uninterrupted decline over the last 50 years while unavoidable death rate shows only small decreases. Cost as per cent of GDP has increased only moderately. There is a correlation between expenses and mortality from avoidable but not from unavoidable diseases, and a large variation in efficiency.
- 5 January 1998
- Published by Wiley in Journal of Internal Medicine
- Vol. 243 (1) , 3-14
On the success, cost and efficiency of modern medicine: an international comparison
Kjellstrand CM, Kovithavongs C, Szabo E (University of Alberta, Edmonton, Canada). On the success, cost and efficiency of modern medicine: an international comparison. J Intern Med 1998; 243: 3–14.Objective: To study the success and cost of modern medicine in industrialized, rich countries from 1980 to 1990.Design: Cost per capita and per cent of gross domestic product (GDP) spent on health was related to: (i) mortality in six diseases amenable to treatment by modern medicine; (ii) the sum of those six diseases (avoidable disease); (iii) death due to other, unavoidable diseases; (iv) maternal and infant mortality; (v) life expectancy at birth; (vi) renal dialysis and transplantation rates. Efficiency was studied by comparing a country's avoidable mortality rates multiplied by expenses, to the mean for all countries.Results: During the 10 years, avoidable death rate decreased 38% but unavoidable death rate only 10%. Life expectancy increased 3%. Cost per capita increased 107% but health expenditures, as per cent of GDP only 10%. There was a reasonable correlation between expenses and avoidable mortality but none between expenses and unavoidable death rate. In 1990 avoidable mortality was lowest in Canada, and highest in Japan. Cost was lowest in New Zealand, and highest in the USA. The efficiency index was highest for Australia, and lowest in the USA.Conclusion: Modern medicine as we have studied it is successful. Avoidable death rate shows a steep uninterrupted decline over the last 50 years while unavoidable death rate shows only small decreases. Cost as per cent of GDP has increased only moderately. There is a correlation between expenses and mortality from avoidable but not from unavoidable diseases, and a large variation in efficiency.